Herzer T, Wagner C A, Waldegger S, Lang F, Busch A E
Physiologisches Institut I, Eberhard-Karls-Universität Tübingen, Germany.
Eur J Pharmacol. 1995 Oct 15;291(2):205-8. doi: 10.1016/0922-4106(95)90144-2.
Inhibition of human IsK channels expressed in Xenopus oocytes by the novel class III antiarrhythmic azimilide was studied under distinct treatments known to increase IsK (hypotonic solution, A23187 and isoproterenol) Azimilide inhibited IsK under all conditions with similar potency. Reduction of ionic strength or pH changes from pH 6.5 to 8.5 did not alter IsK amplitude. However, inhibition of IsK by azimilide was decreased by reduced pH, but not by reduced ionic strength. Further, the apparent affinity of azimilide was increased more than tenfold by increasing pH from 6.5 to 8.5. The data suggest that the neutral form of azimilide, a weak base, inhibits IsK via a lipophilic protein-drug interaction. pH-dependence of azimilide may significantly alter its effects on IsK under distinct pathophysiological conditions (acidosis vs. alkalosis) and in distinct locations (heart vs. kidney).
在已知可增加IsK的不同处理条件(低渗溶液、A23187和异丙肾上腺素)下,研究了新型III类抗心律失常药阿齐利特对非洲爪蟾卵母细胞中表达的人IsK通道的抑制作用。在所有条件下,阿齐利特均以相似的效力抑制IsK。离子强度降低或pH从6.5变为8.5不会改变IsK的幅度。然而,pH降低会降低阿齐利特对IsK的抑制作用,但离子强度降低则不会。此外,将pH从6.5提高到8.5会使阿齐利特的表观亲和力增加十倍以上。数据表明,弱碱性的阿齐利特的中性形式通过亲脂性蛋白质-药物相互作用抑制IsK。阿齐利特的pH依赖性可能会在不同的病理生理条件(酸中毒与碱中毒)和不同位置(心脏与肾脏)下显著改变其对IsK的作用。